Abstract:Topoisomerase I (TOP1) relaxes superhelical DNA through a breakage/rejoining reaction in which the active site tyrosine links covalently to a 3' phosphate at the break site as a transient intermediate. The antitumor drug camptothecin (CPT) and its analogs inhibit the rejoining step of the breakage/rejoining reaction, which traps the enzyme in covalent linkage with DNA (the cleavable complex). Little is known about the fate of cellular TOP1 trapped in the cleavable complex. We have analyzed TOP1 in mammalian cell lines treated with CPT. When CPT-treated cells were lysed with either SDS or alkali and analyzed by Western blotting, greater than 90% of the TOP1 was linked to DNA. Nuclease treatment of the cell lysate to remove the covalently linked DNA from TOP1 revealed a distinct ladder of higher molecular weight bands having properties indicative of multi-ubiquitin (Ub) conjugates of TOP1. Approximately 5-10% of TOP1 was present as these conjugates within minutes of CPT treatment. Consistent with ubiquitination, TOP1 was not modified in ts85 cells at the restrictive temperature for its thermolabile ubiquitin-activating enzyme (E1). Because conjugation with ubiquitin can mark proteins for destruction by the 26S proteasome, we analyzed TOP1 protein levels during prolonged CPT treatment. TOP1 protein levels were reduced to about 25% during CPT treatments of 2-4 h resulting from increased destruction, with the half-life dropping from 10-16 h down to 1-2 h. The destruction of TOP1, like the formation of Ub-TOP1 conjugates, was not observed in ts85 cells at the restrictive temperature. The destruction of TOP1 was also prevented in cells treated with MG-132 and lactacystin, specific inhibitors of the 26S proteasome. Finally, the multi-Ub conjugates of TOP1 were observed whether or not aphidicolin was included in cotreatment with CPT, indicating that replication fork activity was not involved in making TOP1 a substrate for ubiquitination. These results demonstrate that independent of DNA replication, the TOP1 cleavable complex is ubiquitinated and destroyed in cells treated with antitumor drugs that block the religation step of the TOP1 reaction.

Autophagy as a way to remove DNA lesions

TEX264 drives selective autophagy of DNA lesions to promote DNA repair and cell survival

TEX264-mediated selective autophagy directs DNA damage repair

Targeting DNA repair pathways: a novel approach to reduce cancer therapeutic resistance.

Inhibition of Topoisomerase (DNA) I (TOP1): DNA Damage Repair and Anticancer Therapy

Epigenetic control of Topoisomerase 1 activity presents a cancer vulnerability

Autophagy positively regulates DNA damage recognition by nucleotide excision repair.

Autophagy Promotes DNA–protein Crosslink Clearance

Crossing the border: Replication fork adducts move to lysosomes for autophagic repair

TDP1-independent pathways in the process and repair of TOP1-induced DNA damage

111 Autophagy Regulates DNA Repair and Controls Skin Tumorigenesis

Targeting Topoisomerase I in the Era of Precision Medicine

From the TOP: Formation, Recognition and Resolution of Topoisomerase DNA Protein Crosslinks

Ubiquitin-dependent destruction of topoisomerase I is stimulated by the antitumor drug camptothecin

Autophagy suppression in DNA damaged cells occurs through a newly identified p53-proteasome-LC3 axis

Autophagy: A Player in response to Oxidative Stress and DNA Damage

The Role of Single Strand Break Repair Pathways in Cellular Responses to Camptothecin Induced DNA Damage

TEX264 coordinates p97- and SPRTN-mediated resolution of topoisomerase 1-DNA adducts

Topoisomerase I inhibitors: camptothecins and beyond

Autophagy and DNA damage repair

Mechanisms of resistance to topoisomerase I-targeting drugs